Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, with limited survival outcomes due to tumor recurrence, mainly driven by GBM cell invasion and therapy resistance. Although temozolomide (TMZ) remains the standard‐of‐care chemotherapeutic, its long‐term ef...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Victoria A. Kriuchkovskaia, Ela K. Eames, Sydney A. McKee, Paul J. Hergenrother, Rebecca B. Riggins, Brendan A. C. Harley
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley-VCH 2026-06-01
coleção:	Advanced NanoBiomed Research
Assuntos:	chemotherapy resistance glioblastoma (GBM) hydrogel methylguanine methyltransferase (MGMT) temozolomide (TMZ)
Acesso em linha:	https://doi.org/10.1002/anbr.202500244
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!